Navigation Links
Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
Date:3/19/2008

SOUTH EASTON, Mass., March 19 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that researchers from the Company and the Harvard School of Public Health (HSPH) have unveiled a novel approach for the simultaneous extraction, isolation, and fractionation of nucleic acids (DNA and RNA), proteins, and lipids from animal and plant samples routinely used in laboratory research. The method is based on the synergistic combination of the Company's patented pressure cycling technology (PCT), single-use processing containers (PULSE Tubes), and proprietary PCT- enhanced reagents. Presentations on this unique "systems biology" method were made by Dr. Alexander V. Lazarev (PBI) and Dr. Alexander R. Ivanov (HSPH) at the US HUPO (Human Proteomic Organization) 4th Annual Conference, being held March 16-19, in Bethesda Maryland.

Systems biology (SB) refers to the study of the interactions of different biological systems within an organism, which allows scientists to consider the integrated effects of many complex biological interactions. It is hoped that SB studies will result in a more rapid development of diagnostics and therapeutics. Integral to the SB approach is the study of nucleic acids, proteins, and lipids from the same research sample. Unfortunately, very few techniques currently available allow for the concomitant extraction, isolation, and fractionation of these important bio-molecules. Therefore, scientists must rely on mutually incompatible sample preparation methods that result in costly, time-consuming, and problematic processing issues. In their presentations, Dr. Lazarev and Dr. Ivanov unveiled a novel method that they said successfully overcomes the bottleneck issues that face today's systems biology studies. This method also yields high recovery of nucleic acids and proteins, shows excellent reproducibility, and has resulted in the discovery of several unique proteins in certain cancer samples.

Dr. Alexander Lazarev, Vice President of R&D for PBI, said: "The ProteoSolve-LRS ("lipid-rich samples") kit PBI recently released offers researchers a number of advantages over available methods in extracting proteins in lipid-rich samples (used in the study of obesity, diabetes, and heart disease, for example). The new ProteoSolve-SB ("systems biology") kit enhances the LRS kit further, as it offers researchers the ability to simultaneously extract DNA, RNA, and lipids together with proteins from the same initial sample. We believe that this method offers a significant advantage over other extraction methods in use today, and opens up an entirely new market for our PCT products."

Dr. Alexander Ivanov of the Harvard School of Public Health commented: "This is a unique method that can concurrently extract, isolate, and fractionate four major classes of bio-molecules (DNA, RNA, proteins, and lipids) from various cells and tissues. The approach is rapid, reproducible, safe, and provides efficient and high quality bio-molecule recovery. This technique offers the potential to enhance studies in systems biology currently being conducted in a number of laboratories working in many important areas of human, animal, plant, and microbial research."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the use of the Company's Pressure Cycling Technology Sample Preparation System (PCT SPS) for the simultaneous extraction, isolation, and fractionation of nucleic acids, proteins, and lipids from a wide variety of cells and tissues; that the use of the Company's PCT SPS with certain proprietary reagents has advantages over other currently available methods in the extraction of proteins from lipid-rich samples; that nucleic acids, proteins, and lipids can be partitioned separately in a single step and that this "systems biology" approach may lead to the development of important diagnostics and therapeutics; that bio-molecules extracted by the PCT method are done so in a more cost effective, less time-consuming, and less problematic way; that proteins may be extracted by the PCT method that may not be extracted by other current techniques; and the potential markets for the Company's PCT-based products. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology; due to such unforeseen technical difficulties, or marketing, sales, and distribution difficulties, the PCT- dependent systems biology method of bio-molecule extraction may not offer significant advantages over current methods of bio-molecule extraction; that the PCT-dependent, systems biology method of bio-molecule extraction may not be adopted by the scientific community as an accepted method of bio-molecule extraction, or may not help advance scientific research, diagnostic development, or drug discovery; that the PCT-dependent, systems biology method of bio-molecule extraction may not enable the extraction of any proteins not previously extracted by current methods; that other scientists who use the PCT-dependent method of bio-molecule extraction may not achieve the results reported by Dr. Lazarev and Dr. Ivanov; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Sr. Vice President of Finance & CFO

Pressure BioSciences, Inc.

(508) 230-1828 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
3. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
4. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
6. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
7. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
8. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
9. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
10. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
11. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):